Drug intelligence / Profile preview

lipirinen

Development stage
Unknown
Lead developer
Enzymotec
Modality
Small Molecules
Administration
Oral
01

Overview

Lipirinen is a proprietary composition consisting of phosphatidylserine (PS) conjugated to omega-3 fatty acids enriched with eicosapentaenoic acid (EPA). It is the active ingredient in medical foods such as Vayarin and Vay-R, which are orally administered for the clinical dietary management of complex lipid imbalances associated with attention deficit hyperactivity disorder (ADHD), particularly in children[1][2][4]. Lipirinen is designed to address specific lipid nutritional requirements that cannot be met by normal diet or standard dietary supplements. The mechanism of action involves providing essential long-chain polyunsaturated fatty acids important for brain and central nervous system development and function. Phosphatidylserine enriched with omega-3s has been shown to influence neuronal membrane integrity, signal transduction pathways (including regulation of sodium/calcium ATPase and protein kinase C), neurotransmitter activity (acetylcholine, dopamine, noradrenaline), and may increase brain glucose concentrations[2][3]. The exact mechanism by which Lipirinen exerts its effects in ADHD remains not fully understood.

Brand names
VayarinVay-R
Other names
phosphatidylserine-omega-3phosphatidylserine-omega3phosphatidylserine-omega 3PS-Omega-3PS-Omega3PS-Omega 3PS-EPA conjugate
02

Targets

PS (Phosphatidylserine)

Beyond the preview

Go deeper on lipirinen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lipirinen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call